BusinessWeek has a new “Inside Wall Street” article online all about Sonus and why investors see it as a much better bet after Schering’s agreement to help develop Tocosol paclitaxel for the cancer markets. Here it is: http://www.businessweek.com/magazine/content/05_51/b3964083.htm
By the way, since the Schering deal was announced in mid-October and the German company acquired 15 percent of Sonus, Sonus’ stock, trading on Nasdaq under SNUS, is up from $3.95 to $4.73 – about 20 percent. That puts the biotech’s total market value just shy of $143 million as of Friday’s closing price.
Talk to us
- You can tell us about news and ask us about our journalism by emailing newstips@heraldnet.com or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to letters@heraldnet.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.
